Creo Medical has provided a positive trading update for the 6-months to June 2025. The company expects revenues to be £2.2m, up 40% YoY and in-line with management expectations and our FY25 revenue forecasts. Cost reductions and efficiencies are being delivered and positively impacting the company’s performance, with comparable costs down c£4m in 1H25 versus 1H24. Operationally, Creo reports positive momentum in the important US market for its therapeutic endoscopy range of products, while progr ....
